Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Eline Picavet"'
Autor:
Thomas, Morel, André, Lhoir, Eline, Picavet, Segundo, Mariz, Bruno, Sepodes, Jordi, Llinares, David, Cassiman
Publikováno v:
Nature reviews. Drug discovery. 15(6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5c18c57af58a6b0eebc1dfb518f31ed2
https://pubmed.ncbi.nlm.nih.gov/27245390
https://pubmed.ncbi.nlm.nih.gov/27245390
Publikováno v:
Health Policy. 108:1-9
To encourage the development of orphan drugs, the European Union has implemented specific policies in 2000. However, the political, social, scientific and economic context has changed since the implementation of these policies. For that reason, the a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f315fdb7e4ade332e270ae61dffc3aae
https://doi.org/10.1016/j.healthpol.2012.08.023
https://doi.org/10.1016/j.healthpol.2012.08.023
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics. 37:664-667
Summary What is known and Objective: Variations in market uptake of an orphan drug have important implications with respect to access to care and inequality of treatment. Therefore, the aim of this study was to quantify both the sales and volume upta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4200bf8348df269c30787975bf4c4ac4
https://doi.org/10.1111/j.1365-2710.2012.01364.x
https://doi.org/10.1111/j.1365-2710.2012.01364.x
Publikováno v:
Drug Development Research. 73:115-119
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4656492eca7a8bfc327051807c3f6cce
https://doi.org/10.1002/ddr.21005
https://doi.org/10.1002/ddr.21005
Publikováno v:
Expert Review of Pharmacoeconomics & Outcomes Research. 13:571-573
Ethical, legal and social implications of rare diseases and orphan drugs in Europe (Brocher symposium) Geneva, Switzerland 18-19 April 2013 As part of the Scientific Program of the Fondation Brocher, a two-day symposium on orphan drugs and rare disea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::82f96b9e661ee8811d582a71f9b503d6
https://doi.org/10.1586/14737167.2013.832626
https://doi.org/10.1586/14737167.2013.832626
Publikováno v:
Drugs & Therapy Perspectives. 27:24-26
Hospital purchase prices substantially exceed compounding production costs in Belgium for selected orphan drugs that had low costs of research and development and market access procedures. As a result, healthcare payers seem to be paying too much for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3cfa7c9685e9f53865714cec3fdea9dc
https://doi.org/10.2165/11601640-000000000-00000
https://doi.org/10.2165/11601640-000000000-00000
Publikováno v:
Journal of clinical pharmacy and therapeutics. 40(3)
Summary What is known and objective In times of financial and economic hardship, governments are looking to contain pharmaceutical expenditure by focusing on cost-effective drugs. Because of their high prices and difficulties in demonstrating effecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::350f0011d685912ec84751c137948f65
https://pubmed.ncbi.nlm.nih.gov/25891411
https://pubmed.ncbi.nlm.nih.gov/25891411
Publikováno v:
Orphanet Journal of Rare Diseases
Background Most orphan drugs do not meet traditional standards of cost-effectiveness. Yet, most orphan drugs are reimbursed, which implies that other factors are taken into account at the time of reimbursement. To increase accountability of decision-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84642aca34a980270ae8b2d9f905f864
http://europepmc.org/articles/PMC4172832
http://europepmc.org/articles/PMC4172832
Publikováno v:
Orphanet Journal of Rare Diseases
Orphanet journal of rare diseases, 8(1). BioMed Central
Orphanet journal of rare diseases, 8(1). BioMed Central
BACKGROUND: The difficulties associated with organising clinical studies for orphan medicinal products (OMPs) are plentiful. Recent debate on the long-term effectiveness of some OMPs, led us to question whether the initial standards for clinical evid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58e7a5381532036f359155296d510c8f
https://lirias.kuleuven.be/handle/123456789/656029
https://lirias.kuleuven.be/handle/123456789/656029
Publikováno v:
Applied health economics and health policy. 11(1)
In September 2012, the Dutch Healthcare Insurance Board issued advice not to reimburse orphan drugs that target lysosomal storage disorders: agalsidase alfa and agalsidase beta for Fabry disease and alglucosidase alfa for Pompe disease [1, 2].With re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::401f14621dd19f2c0912bed2cac136fa
https://pubmed.ncbi.nlm.nih.gov/23329382
https://pubmed.ncbi.nlm.nih.gov/23329382